Mergers & acquisitions news - Labiotech.eu

Sosei Heptares hails ‘transformational’ acquisition

Jim Cornall — Thu, 20 Jul 2023 09:34:31 +0000

Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and APAC territory rights, with the exception of China, to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ (clazosentan) already commercially available and […]

The post Sosei Heptares hails ‘transformational’ acquisition appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Korro Bio and Frequency Therapeutics to merge

Jim Cornall — Tue, 18 Jul 2023 09:47:03 +0000

Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to […]

The post Korro Bio and Frequency Therapeutics to merge appeared first on Labiotech.eu.

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

Jim Cornall — Tue, 18 Jul 2023 09:00:00 +0000

DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its fatty acid ligand conjugated oligonucleotide (FALCON) platform, has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma’s lead […]

The post Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma appeared first on Labiotech.eu.

Lilly boosts obesity portfolio with Versanis Bio acquisition

Jim Cornall — Mon, 17 Jul 2023 15:25:13 +0000

Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […]

The post Lilly boosts obesity portfolio with Versanis Bio acquisition appeared first on Labiotech.eu.

Brace yourself for a wave of biotech layoffs

Roohi Mariam Peter — Thu, 22 Jun 2023 09:00:00 +0000

In the ever-evolving field of biotechnology spearheaded by discoveries that fuel therapeutic success, of late, the industry is taking measures to optimize the workforce amid economic uncertainty. Or to put it plainly, the biotech industry is now faced with a string of layoffs. And following the lead of big pharmas like AbbVie and Bristol Myers […]

The post Brace yourself for a wave of biotech layoffs appeared first on Labiotech.eu.

Novartis acquires Chinook Therapeutics for $3.2B

Jim Cornall — Fri, 16 Jun 2023 09:30:00 +0000

Novartis has entered into an agreement to acquire Chinook Therapeutics, a Seattle, Washington, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed deal, which is subject to customary closing conditions, is in line with Novartis’ strategy to focus on innovative medicines and will expand […]

The post Novartis acquires Chinook Therapeutics for $3.2B appeared first on Labiotech.eu.

Beyond Biotech podcast 49

Jim Cornall — Fri, 09 Jun 2023 10:04:17 +0000

This week, we have a conversation about precision medicine with Tero Silvola, CEO at BC Platforms. We also discuss the acquisition of 4Pharma. The acquisition expands BCP’s global service offering for accelerating the translation of innovations into clinical practice. In addition, 4Pharma customers will benefit from additional services in the field of RWD through the […]

The post Beyond Biotech podcast 49 appeared first on Labiotech.eu.

Lonza boosts ADC portfolio with Synaffix acquisition

Jim Cornall — Thu, 01 Jun 2023 08:31:36 +0000

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs). While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which […]

The post Lonza boosts ADC portfolio with Synaffix acquisition appeared first on Labiotech.eu.

Novartis buys AVROBIO cystinosis gene therapy program for $87.5M

Jim Cornall — Fri, 26 May 2023 08:10:00 +0000

AVROBIO, Inc., a clinical-stage gene therapy company working to free people from a lifetime of genetic disease, has agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for […]

The post Novartis buys AVROBIO cystinosis gene therapy program for $87.5M appeared first on Labiotech.eu.

Ironwood acquires VectivBio in $1B deal

Jim Cornall — Tue, 23 May 2023 08:18:49 +0000

Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, and VectivBio Holding AG, a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1 billion, net of VectivBio […]

The post Ironwood acquires VectivBio in $1B deal appeared first on Labiotech.eu.

Gilead boosts oncology pipeline with XinThera acquisition

Jim Cornall — Tue, 09 May 2023 14:00:00 +0000

Gilead Sciences, Inc. has announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. Gilead Sciences said the acquisition complements its existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead Sciences gains the rights to a portfolio […]

The post Gilead boosts oncology pipeline with XinThera acquisition appeared first on Labiotech.eu.

Recursion boosts drug discovery with Cyclica and Valence acquisitions

Jim Cornall — Tue, 09 May 2023 10:00:00 +0000

Recursion has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica, for $40 million, and Valence, for $47.5 million. Chris Gibson, co-founder and CEO of Salt Lake City headquartered Recursion, said: “Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology […]

The post Recursion boosts drug discovery with Cyclica and Valence acquisitions appeared first on Labiotech.eu.

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Jim Cornall — Tue, 02 May 2023 10:30:00 +0000

Astellas Pharma Inc., through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio, Inc., for $40 per share in cash for a total equity value of approximately U.S. $5.9 billion. Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. […]

The post Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover appeared first on Labiotech.eu.

Australian biopharma Telix banks on AI with Dedicaid acquisition

Jim Cornall — Thu, 27 Apr 2023 11:08:27 +0000

Australian biopharma company Telix Pharmaceuticals Limited is expanding its artificial intelligence (AI) capability with the signing of an agreement to acquire Austria-based Dedicaid GmbH, a spin-off of the Medical University Vienna. Dedicaid’s core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use […]

The post Australian biopharma Telix banks on AI with Dedicaid acquisition appeared first on Labiotech.eu.

Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition

Jim Cornall — Wed, 05 Apr 2023 13:00:00 +0000

Ginkgo Bioworks has acquired StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets. A secondary close is scheduled upon the transfer of certain additional in-license agreements to Ginkgo Bioworks. Ginkgo Bioworks will incorporate the assets and IP into its end-to-end AAV gene therapy development platform, allowing the company’s customers to leverage new tools to […]

The post Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition appeared first on Labiotech.eu.

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

Jim Cornall — Tue, 14 Mar 2023 12:11:39 +0000

Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that discovers, develops and commercializes cancer medicines. The boards of directors of both companies have unanimously approved the transaction. “Pfizer is deploying its financial resources to […]

The post Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline appeared first on Labiotech.eu.

Sanofi adds diabetes drug through Provention Bio $2.9B acquisition

Jim Cornall — Mon, 13 Mar 2023 16:30:21 +0000

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds […]

The post Sanofi adds diabetes drug through Provention Bio $2.9B acquisition appeared first on Labiotech.eu.

5 steps to strategic partnerships for healthtech startups

External Contributor — Thu, 02 Mar 2023 11:41:48 +0000

By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma expertise and infrastructure, which significantly […]

The post 5 steps to strategic partnerships for healthtech startups appeared first on Labiotech.eu.

GC Biopharma acquiring hemophilia rare disease pipeline

Jim Cornall — Tue, 28 Feb 2023 11:01:02 +0000

GC Biopharma Corp., a South Korean provider of biopharmaceutical products, has signed an asset purchase agreement with Catalyst Biosciences to acquire three programs related to the orphan hematology disorders. The agreement includes Marzeptacog alfa (MarzAA), an engineered factor VIIa, which is ready for phase 3 clinical stage development. In its previous clinical development trials, MarzAA […]

The post GC Biopharma acquiring hemophilia rare disease pipeline appeared first on Labiotech.eu.

Crown Bioscience acquiring Indivumed’s service business and biobank

Jim Cornall — Thu, 02 Feb 2023 11:18:44 +0000

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A share purchase agreement (SPA) between was executed in December, 2022, and subject to customary closing adjustments, the transaction is expected to close in April 2023. Indivumed […]

The post Crown Bioscience acquiring Indivumed’s service business and biobank appeared first on Labiotech.eu.